IBB News Alert Nasdaq Biotechnology Ishares (IBB) 323.46 02/14/2015

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nasdaq Biotechnology Ishares (IBB) 323.46 $IBB

Pharma And Biotech Funds Add Zest To Your Portfolio
John Dowdee - at Seeking Alpha - Fri Feb 13, 7:10AM CST

PBE: 52.78 (+0.30), HQL: 27.40 (+0.16), FBT: 110.21 (+1.02), PJP: 73.81 (+0.69), XBI: 203.40 (+1.36), XPH: 118.58 (+0.98), IBB: 323.46 (+3.04), HQH: 34.20 (+0.06)

On The Cusp Of Raising Rates?
Leo Kolivakis - Seeking Alpha - Fri Feb 06, 12:59PM CST
Lucia Mutikani of Reuters reports, Strong U.S. job, wage gains open door to mid-year rate hike : U.S. job growth rose solidly in January and wages rebounded strongly, a show of underlying strength in the economy that puts a mid-year interest rate...
XLB: 51.44 (+0.43), QQQ: 106.91 (+0.91), XBI: 203.40 (+1.36), IBB: 323.46 (+3.04), XLK: 42.65 (+0.27), IWM: 121.53 (+0.72), TWTR: 48.50 (+0.55), XLU: 45.17 (-0.70), XLV: 70.72 (+0.28), GSG: 21.18 (+0.43), XLE: 82.04 (+1.70)

Gilead, Amgen Q4 Earnings And Weak Outlook Affect Biotech ETFs
Zacks Funds - Seeking Alpha - Fri Feb 06, 6:17AM CST
The biotech sector stood out last year and the NASDAQ Biotechnology Index delivered a stellar 34% return for 2014. Despite some temporary glitches and rough trading in between, encouraging industry trends, increasing merger and acquisition...
PBE: 52.78 (+0.30), BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), ALXN: 182.29 (+6.02), BBH: 122.45 (+0.86), IBB: 323.46 (+3.04), AMGN: 153.48 (+0.30)

Gilead, Amgen Q4 Earnings & Weak Outlook Affect Biotech ETFs - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 1:01AM CST
Concerns about pricing pressure are weighing on the overall performance of the biotech sector putting these ETFs in focus.
PBE: 52.78 (+0.30), BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), ALXN: 182.29 (+6.02), BBH: 122.45 (+0.86), IBB: 323.46 (+3.04), AMGN: 153.48 (+0.30)

Biotech Stocks Blasted! Now’s the Time to “Buy the Dip”
Greg Guenthner - Daily Reckoning - Thu Feb 05, 8:49AM CST
This post Biotech Stocks Blasted! Now’s the Time to “Buy the Dip” appeared first on Daily Reckoning . The biotech sector posted 30%-plus gains during the first eight weeks of 2014. And while this was an active trader's...
GILD: 101.90 (+1.10), IBB: 323.46 (+3.04)

iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 1.65%
Comtex SmarTrend(R) - Wed Feb 04, 3:37PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $305.01 to a high of $314.68. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $310.13 on volume of 3.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 323.46 (+3.04)

Watch for iShares Nasdaq Biotechnology Index to Potentially Rebound After Falling 1.65% Yesterday
Comtex SmarTrend(R) - Wed Feb 04, 3:37PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $305.01 to a high of $314.68. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $310.13 on volume of 3.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 323.46 (+3.04)

Oil, Earnings, Strong U.S. Dollar Keeping Stocks in 'No Man's Land'
at The Street - Wed Feb 04, 1:26PM CST
The CNBC 'Fast Money Halftime' trading panel looks at stocks and how they will perform in 2015, as well as at earnings results from Chipotle Mexican Grill and Gilead Sciences. 
USO: 19.62 (+0.44), XBI: 203.40 (+1.36), AMGN: 153.48 (+0.30), DIS: 104.17 (+0.59), IBB: 323.46 (+3.04), TLT: 128.19 (-1.33), CELG: 115.88 (+0.16), GT: 25.91 (-0.30), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), GILD: 101.90 (+1.10), CMG: 674.89 (+4.60), DIA: 180.34 (+0.50), BP: 41.93 (+0.59), IWM: 121.53 (+0.72), XLE: 82.04 (+1.70), CL: 70.08 (+0.23)

Today's Market: Stocks On The Rise, Blowout Earnings And Dividend Increases
Matthew Smith - at Seeking Alpha - Wed Feb 04, 9:44AM CST

SPLS: 16.86 (-0.22), AMZN: 381.83 (+4.66), BIIB: 391.66 (-0.45), WMT: 85.81 (-0.08), AMGN: 153.48 (+0.30), DIS: 104.17 (+0.59), IBB: 323.46 (+3.04), M: 64.32 (-0.34), CELG: 115.88 (+0.16), WHR: 213.23 (+0.18), GILD: 101.90 (+1.10), TGT: 76.12 (-0.75), GM: 37.62 (-0.40), ODP: 9.59 (-0.02)

Biotech selling off early
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 9:04AM CST

BIB: 141.30 (+2.39), IBB: 323.46 (+3.04)

Volatility Continues As Earnings Reports Create Excitement And Despair
Scott Martindale - at Seeking Alpha - Mon Feb 02, 9:02PM CST
Volatility reigned in January on elevated volume as stock investors shifted their focus from global events to U.S. earnings reports, which have ranged from amazing (e.g., Apple) to crushing (e.g., Microsoft). Although the earnings reports have...
IYK: 106.66 (-0.09), BIIB: 391.66 (-0.45), CAVM: 62.86 (-0.55), IYJ: 109.15 (+0.67), KBWD: 25.26 (-0.02), IYH: 149.63 (+0.84), IYM: 86.13 (+0.83), IYC: 142.85 (+0.77), IBB: 323.46 (+3.04), SMH: 56.39 (+0.33), IT: 81.53 (+1.64), IYF: 90.01 (-0.04), IYE: 46.47 (+0.95), STWD: 24.24 (-0.10), IYZ: 30.91 (+0.12), SPY: 209.78 (+0.86), SUI: 66.58 (-0.57), IDU: 113.30 (-1.71), SHPG: 239.82 (+6.11), IYW: 107.68 (+0.94)

Some Pre-Earnings Release Observations About Gilead Sciences
DoctoRx - at Seeking Alpha - Mon Feb 02, 10:02AM CST

JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), IBB: 323.46 (+3.04), ABBV: 58.05 (+1.00)

Is the 'January Effect' Signaling a Down Year for the Stock Market?
at The Street - Fri Jan 30, 2:14PM CST
CNBC's 'Fast Money Halftime' trading panel took a look at how stocks have shaped up for the first month of 2015 and what that means for the next 11 months.
AMZN: 381.83 (+4.66), BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), FEYE: 42.26 (+2.63), SHAK: 40.69 (+0.04), IBB: 323.46 (+3.04), EEQ: 37.09 (-0.36), TLT: 128.19 (-1.33), SPY: 209.78 (+0.86), SONC: 31.59 (-0.37), QQQ: 106.91 (+0.91), GILD: 101.90 (+1.10), CMG: 674.89 (+4.60), DIA: 180.34 (+0.50), MCD: 95.65 (+0.56), IWM: 121.53 (+0.72)

A Time To Cheer Or A Time To Cry
Papa of Four - at Seeking Alpha - Fri Jan 30, 10:22AM CST

USO: 19.62 (+0.44), BIIB: 391.66 (-0.45), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), GLD: 117.98 (+0.64), DIA: 180.34 (+0.50), IBB: 323.46 (+3.04), SLV: 16.54 (+0.39), AAPL: 127.08 (+0.62)

IBB Is +34% For 1 Year And +7.31% For 2015 - But What Are The Risks?
Reuben Sushman - at Seeking Alpha - Fri Jan 30, 9:07AM CST

VRTX: 113.66 (+4.03), Q: 63.31 (+0.06), IBB: 323.46 (+3.04), CELG: 115.88 (+0.16)

Will You Miss The Netflix Ride To $1,000?
John Haigh - at Seeking Alpha - Tue Jan 27, 10:16AM CST

NFLX: 466.10 (+9.37), IBB: 323.46 (+3.04), DISH: 77.20 (-0.16), TWX: 83.87 (+0.56)

Tech ETF IBB Brings Plenty Of Risk But It Fits Nicely In A Portfolio
ColoradoWealthManagementFund - at Seeking Alpha - Tue Jan 27, 9:14AM CST

IBB: 323.46 (+3.04)

SmarTrend Watching for Potential Pullback in Shares of iShares Nasdaq Biotechnology Index After 1.73% Gain
Comtex SmarTrend(R) - Mon Jan 26, 3:52PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $321.15 to a high of $328.32. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $323.31 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 323.46 (+3.04)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

PrideStaff's New Office Location Elevates Service Experience

Updated Category News Views 130

PrideStaff Relocates to a Central Location for Better Service PrideStaff, a nationally franchised staffing organization, is excited to announce the relocation of its Visalia office to 123 South Church Street. This move symbolizes a commitment to improved service for clients and candidates in Central Valley. New Location Enhances Accessibility Situated near Main Street and...

Continue Reading
Nidec Corp Faces Scrutiny Amid Ongoing Investigations

Updated Category News Views 238

Understanding the Current Situation of Nidec Corporation Nidec Corporation (OTC: NJDCY) has recently found itself in troubled waters as allegations emerge concerning its accounting practices. The company has established a third-party committee to investigate these concerns, following suspicions of inappropriate financial reporting. Investments at Risk: What Happened?...

Continue Reading
Thyristor and IGCT Market Rapid Growth Forecast Until 2034

Updated Category News Views 117

Thyristor and IGCT Market Overview The Thyristor and IGCT market is emerging as a key player in the power electronics industry, showing promising growth from USD 2.1 billion recently to an anticipated USD 3.5 billion by 2034. This upward trend equates to a compound annual growth rate (CAGR) of 5.3% during the forecast period. Drivers of Market Growth Increasing Demand for...

Continue Reading
Indivior PLC Faces Legal Challenge: A Call for Investors to Act

Updated Category News Views 198

Indivior PLC Under Legal Scrutiny: What Investors Should Know Investors now have a notable chance to take the lead in a class action lawsuit against Indivior PLC (NASDAQ: INDV), due to serious allegations of securities fraud. The ongoing legal battles have created unease among shareholders and could open a path for investors who experienced significant losses and are...

Continue Reading
Bybit and Block Scholes Reveal Market Insights for ETH and SOL

Updated Category News Views 119

Market Insights from Bybit and Block Scholes Bybit, recognized as the world's second-largest cryptocurrency exchange by trading volume, recently shared its insightful report in collaboration with Block Scholes. The results showcase significant market movements, particularly with Ethereum (ETH) and Solana (SOL). Market players are keenly observing these developments as...

Continue Reading